Applicability of the MARS Therapy in patients with hepatic conditions
Section: Revisiones
How to quote
Girón Poves G, Ruiz García P, Infante Garza M, Leal Costa C, Días Agea JL. Aplicabilidad de la terapia MARS en pacientes con patología hepática. Metas Enferm jul/ago 2018; 21(6):58-62.
Authors
Gema Girón Poves1, Pablo Ruiz García1, Miriam Infante Garza1, César Leal Costa2, José Luis Díaz Agea2
Position
1Máster Universitario en Enfermería de Urgencias, Emergencias y Cuidados especiales. Universidad Católica de Murcia (UCAM)2Doctor. Profesor Contratado Doctor. Universidad Católica de Murcia (UCAM)
Contact address
Gema Girón Poves. Avda. Ramón Menéndez Pidal, 46. 02005 Albacete.
Contact email: girong8@gmail.com
Abstract
Objective: to identify the indications of MARS therapy in patients with liver failure or impairment.
Method: a narrative review of articles published from 2012 to 2017 in the bibliographic databases Pubmed, Web of Science and Cochrane, evaluating treatment success for MARS therapy in patients with liver failure or impairment. Clinical trials, observational studies and case studies were included; while cross-sectional studies were excluded.
Results: thirteen (13) articles were selected: eight clinical trials and five case studies. MARS therapy was applied in patients with renal failure without a specific etiology, associated with intoxications, with liver encephalopathy as complication; in subjects who also presented cardiopulmonary failure and were connected to ECMO (extra-corporeal membrane oxygenation), in patients on the waiting list for transplant, or after undergoing transplant.
Conclusion: certain controversies were detected regarding the application of MARS therapy in patients with liver failure or impairment. The indication with the highest support by the studies reviewed regarding the application of MARS therapy was the case of patients in the waiting list for a liver transplant.
Keywords:
Liver failure; critical care; liver transplant
Versión en Español
Título:
Aplicabilidad de la terapia MARS en pacientes con patología hepática